Tackling the challenge of enhancing cytotoxic payload potency while reducing off-target toxicity in ADCs
18 Jun 2025
Cytotoxic Payload
- How can we improve the potency of cytotoxic payloads without increasing off-target toxicity in ADCs?
- What strategies can be implemented to ensure selective payload delivery to tumor cells while minimizing collateral damage to healthy tissues?
- How do different cytotoxic payload classes (e.g., auristatins, maytansinoids) compare in terms of potency and selectivity?
- What role do payload-linker interactions play in controlling the release of the cytotoxic agent, specifically at the tumor site?
- How can we better predict and mitigate systemic toxicity from potent cytotoxic payloads in clinical ADC development?